| Literature DB >> 23350847 |
Fernando Padilla1, Niala Bhagirath, Shaoqing Chen, Eric Chiao, David M Goldstein, Johannes C Hermann, Jonathan Hsu, Joshua J Kennedy-Smith, Andreas Kuglstatter, Cheng Liao, Wenjian Liu, Lee E Lowrie, Kin Chun Luk, Stephen M Lynch, John Menke, Linghao Niu, Timothy D Owens, Counde O-Yang, Aruna Railkar, Ryan C Schoenfeld, Michelle Slade, Sandra Steiner, Yun-Chou Tan, Armando G Villaseñor, Ce Wang, Jutta Wanner, Wenwei Xie, Daigen Xu, Xiaohu Zhang, Mingyan Zhou, Matthew C Lucas.
Abstract
We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies. Ultimately, our mouse model revealed unexpected toxicity that precluded us from further advancing this series.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23350847 DOI： 10.1021/jm301720p
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446